References

Patient References

  1. SYNVISC®/Synvisc-One® Product Monographs, Genzyme Canada Inc., July 18, 2008/March 2, 2009.
  2. Genzyme Canada Inc. Synvisc (Hylan G-F 20) – A Step Ahead. Accessed online at www.synvisccanada.com [03/12/2013].
  3. Waddell DD, et al. Journal of Managed care Pharmacy. 2007;13(2):113-121.
  4. The Arthritis Society. Osteoarthritis – Know Your Options. 11. Brochure accessed online at www.arthritis.ca [03/12/2013].
  5. Genzyme Inc. Synvisc (Hylan G-F 20) – Osteoarthritis Knee Pain Relief Treatment. Accessed online at www.synviscone.com [03/12/2013].
  6. Stitik TP, et al. Future Rheumatol. 2008;3(3):215-222.
  7. Raman R, et al. The Knee. 2008:15:318-324.
  8. Langworthy MJ, et al. The Physician and Sports Medicine. 2010;38(2):133-145.
  9. Manek NJ and Lane NE. Am. Fam. Physician. 2000;61(6):1795-804.
  10. Hinton R et al. Am Fam Physician. 2002;65:841-848.
  11. Jordan KM, et al. Ann Rheum Dis. 2003;62:1145–1155.
  12. Lussier A, et al. Journal of Rheumatology.1996;9(23):1579-1585.

Healthcare Professionals References

  1. SYNVISC®/Synvisc-One® Product Monographs, Genzyme Canada Inc., July 18, 2008/March 2, 2009.
  2. Raman R, et al. Safety and Efficacy of Repeat Treatment with Single dose Hylan G-F 20 in osteoarthritis of the knee. Poster presented at: The Annual meeting of American Academy of Orthopedic Surgeons; Feb 15-19, 2011; San Diego, USA.
  3. Conrozier T, et al. Arch Orthop Trauma Surg. 2009;129(3):417-423.
  4. Lussier A, et al. Journal of Rheumatology.1996;9(23):1579-1585.
  5. US FDA Device Listings Database and Pharmacopeia. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=3960&Ipcd=MOZ. Accessed December 2009.
  6. Stitik TP, et al. Future Rheumatol. 2008;3(3):215-222.
  7. Raynauld JP, et al. OsteoArthritis and Cartilage. 2005;13:111-119.
  8. Waddell DD, et al. Journal of Managed care Pharmacy. 2007;13(2):113-121.
  9. Marshall KW, et al. Journal of Orthopaedic Research. 2000;18:416-425.
  10. Li P, et al. Osteoarthritis Cartilage. 2012:20(11):1336-1346.
  11. Wang Y, et al. BMC Musculoskelet Disord. 2011;12:195.
  12. Hall S, et al. Poster presented at: European League Against Rheumatism (EULAR); June 16-19, 2010; Rome, Italy.
  13. Chevalier X, et al. Ann Rheum Dis. 2010;69:113-119.
  14. Langworthy MJ, et al. The Physician and SportsMedicine. 2010;38(2):133-145.
  15. Jordan KM, et al. Ann Rheum Dis. 2003;62:1145–1155.
  16. Zhang W, et al. Osteoarthritis and Cartilage. 2008;16:137-162.
  17. Health Canada. Basic Product Monograph Information for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). 2006. File Number: 06-125744-338.
  18. Aleve Product Monograph, Bayer Inc. July 17, 2009.
  19. Apo-Diclo Product Monograph, APOTEX Inc. September 24, 2009.
  20. Schnitzer, Thomas J. Journal of Pain and Symptom Management. 2002;23(4S):S24-S30.
  21. American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the Knee (Non-Arthroplasty) – Full Guidelines. December 6, 2008.
  22. M-Eslon Product Monograph, Ethypharm Inc. May 26, 2006.
  23. OxyContin Product Monograph, Purdue Pharma. April 24, 2006.
  24. Raman R, et al. The Knee. 2008:15:318-324.
  25. The Arthritis Society. Osteoarthritis – Know Your Options. 11. Brochure accessed online at www.arthritis.ca [03/12/2013].
  26. Burbine SA, et al. Projecting the Future Public Health Impact of the Trend Toward Earlier Onset of Knee Osteoarthritis in the Past 20 Years. Chicago, IL: ACR/ARHP Scientific Meeting.
Fill out my online form.

Synvisc-One®

Synvisc-One is a treatment to decrease pain and discomfort associated with osteoarthritis that replaces the diseased synovial fluid in your knee with a gel-like substance that is very similar to the synovial fluid found in healthy, young joints.

Synvisc-One®

What is Synvisc-One
Part of Your OA Plan
Patient Stories
OnTRACK

Understand Osteoarthritis

Osteoarthritis and You
Treatment Options​​​​​​​

Find a clinic near you

Find a clinic near you
Before Appointment
After Appointment
Insurance Coverage